U.S. Continues to Lead New Drug R&D, but Asia-Pacific is Starting to Rise, According to the Tufts Center for the Study of Drug Development
January 08, 2019 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Recent launches of new active substances (NAS) and a strong R&D pipeline indicate that recent global drug development not only has been robust, but also...
UPDATE - Hikma Pharmaceutical Plants Sold to Investor Group
January 02, 2019 17:27 ET
|
Gordon Brothers
Eatontown, New Jersey, Jan. 02, 2019 (GLOBE NEWSWIRE) -- A joint venture between Gordon Brothers and New Mill Capital Holdings has acquired three buildings from Hikma Pharmaceuticals in the...
Hikma Pharmaceutical Plants Sold to Investor Group
January 02, 2019 16:39 ET
|
Gordon Brothers
Eatontown, New Jersey, Jan. 02, 2019 (GLOBE NEWSWIRE) -- A joint venture between Gordon Brothers (www.gordonbrothers.com) and New Mill Capital Holdings (www.newmillcapital.com) has acquired three...
Global Biotech Product Development Expected to Continue Its Multi-Decade Surge, According to the Tufts Center for the Study of Drug Development
November 13, 2018 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- With more than 500 Phase III clinical trials now underway for biotech products worldwide, the multi-decade surge in new biopharmaceutical approvals is...
Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation
November 07, 2018 08:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE:31R) ("Revive" or the “Company”), a specialty cannabis company focused on the research,...
InveniAI®’s Innovation Monitoring Platform, AlphaMeld™, Witnesses Rapid Uptake in BioPharma and Adjacencies
October 17, 2018 12:00 ET
|
InveniAI
Platform built to detect the earliest signs of innovation in real-time and across industries BRANFORD, Conn., Oct. 17, 2018 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader in pioneering...
Nanobiotix reçoit un versement initial de 16 millions d’euros au titre du prêt accordé par la Banque Européenne d’Investissement
October 16, 2018 02:13 ET
|
NANOBIOTIX
Nanobiotix reçoit un versement initial de 16 millions d’euros au titre du prêt accordé par la Banque Européenne d’Investissement Le produit sera utilisé pour accélérer le développement du produit...
Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank
October 16, 2018 02:13 ET
|
NANOBIOTIX
Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank Proceeds will be used to speed up development of pioneering lead product NBTXR3 and to...
CNS Drugs Take 20% Longer to Develop and 38% Longer to Approve vs. Non-CNS Drugs, According to the Tufts Center for the Study of Drug Development
September 11, 2018 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Developing drugs to treat central nervous system (CNS) disorders on average required 20% more time than other drugs that won marketing approval in the...
Satellite Launch Vehicle (SLV) Market worth $2.4bn by 2024: Global Market Insights, Inc.
August 29, 2018 07:00 ET
|
Global Market Insights, Inc
Sellbyville, Delaware, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Satellite Launch Vehicle (SLV) Market is set to surpass USD 2.4 billion by 2024; according to a new research report by Global Market...